Video Experimental Relacionado
Updated: Jul 21, 2026
09:45
Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
Published on: April 27, 2017
Inhibidores de la enzima convertidora de angiotensina: un nuevo mecanismo de acción
Hongmei Peng1, Oscar A Carretero, Nikola Vuljaj
1Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, MI 48202-2689, USA.
Circulation
|October 12, 2005
Resumen
Los inhibidores de la enzima de conversión de la angiotensina (ECA) reducen la fibrosis cardíaca en la hipertensión al bloquear la descomposición de la N-acetil-seril-aspartil-lisil-prolina (Ac-SDKP). Este nuevo mecanismo disminuye la inflamación, la proliferación celular y la deposición de colágeno, ofreciendo nuevos conocimientos terapéuticos.
Área de la Ciencia:
- Investigaciones Cardiovasculares Investigación Cardiovascular Investigaciones Cardiovasculares
- Farmacología Farmacología.
- Medicina renal Medicina renal es la especialidad de la medicina renal.
Sus antecedentes:
- Los inhibidores de la enzima convertidora de angiotensina (ECA) son cruciales para el manejo de la hipertensión, la insuficiencia cardíaca y la enfermedad renal.
- Sus efectos cardioprotectores provienen de la inhibición de la formación de angiotensina II y la hidrólisis de la quinina.
- Se explora un nuevo mecanismo que involucra la hidrólisis de N-acetil-seril-aspartil-lisil-prolina (Ac-SDKP) para la acción antifibrótica del inhibidor de la ECA.
Objetivo del estudio:
- Para investigar el papel de Ac-SDKP en los efectos antifibróticos del inhibidor de la ECA captopril.
- Para dilucidar el mecanismo por el cual los inhibidores de la ECA reducen la fibrosis cardíaca en un modelo de hipertensión.
Principales métodos:
- Utilizó un modelo de ratas de la hipertensión inducida por la angiotensina II (Ang II).
- Inhibidor de la ECA (captopril) administrado solo o con un anticuerpo monoclonal bloqueador (mAb) al Ac-SDKP.
- Se evaluó la hipertrofia ventricular izquierda (LVH), la fibrosis cardíaca, la proliferación celular, la expresión de TGF-beta y la fosforilación de Smad2.
Principales resultados:
- Los inhibidores de la ECA redujeron significativamente la deposición de colágeno cardíaco, la inflamación y la proliferación celular, a pesar de no reducir la presión arterial o la LVH.
- Estos efectos antifibróticos fueron anulados por el anti-Ac-SDKP mAb, lo que indica el papel crucial de Ac-SDKP.
- El inhibidor de la ECA disminuyó la expresión de TGF-beta y la fosforilación de Smad2, que fue revertida por el mAb.
Conclusiones:
- Los inhibidores de la ECA ejercen efectos antifibróticos cardíacos en la hipertensión al inhibir la hidrólisis de Ac-SDKP.
- Esta inhibición conduce a una reducción de la proliferación de células cardíacas, la infiltración inflamatoria, la señalización de TGF-beta y la deposición de colágeno.
- Los hallazgos revelan una nueva vía para los beneficios terapéuticos de los inhibidores de la ECA en las enfermedades cardiovasculares.
Videos de Conceptos Relacionados
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...